Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection. (11th August 2017)

• Record Type: Journal Article
• Authors: Prabhu, Vimalanand S; Cornely, Oliver A; Golan, Yoav; Dubberke, Erik R; Heimann, Sebastian M; Hanson, Mary E; Liao, Jane; Pedley, Alison; Dorr, Mary Beth; Marcella, Stephen
• Is Part Of: Clinical infectious diseases. Volume 65:Number 7(2017)
• Page Start: 1218
• Page End: 1221
• Publication Date: 2017-08-11
• Subjects: C. difficile infection -- recurrence -- hospital readmissions -- bezlotoxumab; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/cix523
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: We estimated 30-day all-cause and Clostridium difficile infection (CDI)–associated hospital readmissions in participants at high risk of recurrent CDI enrolled in MODIFY I/II. Bezlotoxumab-treated inpatients experienced fewer CDI-associated readmissions compared with placebo-treated inpatients, notably in participants aged ≥65 years and with severe CDI. Clinical Trials Registration. NCT01241552 (MODIFY I) and NCT01513239 (MODIFY II).